Literature DB >> 8909329

Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders.

R J Baldessarini1, L Tondo, G L Faedda, T R Suppes, G Floris, N Rudas.   

Abstract

BACKGROUND: Gradual discontinuation of lithium may reduce high risk of early morbidity in bipolar disorder patients discontinuing successful long-term maintenance on lithium, but previous small samples have limited analyses of subgroups.
METHOD: DSM-IV bipolar disorder patients (N = 161) were pooled from similar samples maintained on lithium for 4.2 +/- 3.1 years. Effects of discontinuing treatment abruptly (1-14 days) or gradually (15-30 days) were compared by survival analysis in clinically closely similar groups.
RESULTS: After gradual versus rapid discontinuation, the overall median time to recurrence +/- SE differed by 5.0-fold (20.0 +/- 5.8 vs. 4.0 +/- 0.7 months; p < .0001). After rapid discontinuation, the median time in remission was 2.3 times shorter than the mean cycling interval before lithium (6.3 vs. 14.6 months; p < .0001). The proportion of subjects falling ill/month (recurrence rate) was much higher in the first year after rapid discontinuation (6.5% vs. 2.3%), but similar thereafter (0.4% vs. 0.6%); patients remained stable for 3 years when off lithium treatment 20 times more frequently after gradual than rapid discontinuation (37% vs. 1.8%; p < .0001). Ratios of median survival times after gradual/rapid lithium discontinuation were similar for a first recurrence of mania and depression (4.4 vs. 3.4-fold), insignificantly higher (34%) with rapid or continuous cycling before lithium, and greater in Type II than Type I disorder (9.8- vs. 4.0-fold). The polarity of first off-lithium and first lifetime episodes matched in 70% of cases.
CONCLUSION: These pooled results strengthen the concept or a pharmacodynamic stress factor in early relapse after stopping lithium maintenance and support the conclusion that early recurrence risk can be minimized by discontinuing maintenance treatment gradually in both Type I and II bipolar disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909329     DOI: 10.4088/jcp.v57n1001

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  If devolved facilities are used, processes may be streamlined

Authors: 
Journal:  BMJ       Date:  1998-09-19

Review 2.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

3.  Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study.

Authors:  Robert L Findling; Nora K McNamara; Mani Pavuluri; Jean A Frazier; Moira Rynn; Russell Scheffer; Vivian Kafantaris; Adelaide Robb; Melissa DelBello; Robert A Kowatch; Brieana M Rowles; Jacqui Lingler; Jian Zhao; Traci Clemons; Karen Martz; Ravinder Anand; Perdita Taylor-Zapata
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-11-26       Impact factor: 8.829

4.  Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior.

Authors:  Maria A Oquendo; Hanga C Galfalvy; Dianne Currier; Michael F Grunebaum; Leo Sher; Gregory M Sullivan; Ainsley K Burke; Jill Harkavy-Friedman; M Elizabeth Sublette; Ramin V Parsey; J John Mann
Journal:  Am J Psychiatry       Date:  2011-07-18       Impact factor: 18.112

Review 5.  Medication nonadherence in bipolar disorder: a narrative review.

Authors:  Ibrahim Jawad; Stuart Watson; Peter M Haddad; Peter S Talbot; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-16

Review 6.  Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature.

Authors:  Alexander C Tsai; Nicholas Z Rosenlicht; Jon N Jureidini; Peter I Parry; Glen I Spielmans; David Healy
Journal:  PLoS Med       Date:  2011-05-03       Impact factor: 11.069

7.  Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Paul Grof; Guy A Rouleau; Gustavo Turecki
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

8.  Suicide risk in Veterans Health Administration patients with mental health diagnoses initiating lithium or valproate: a historical prospective cohort study.

Authors:  Eric G Smith; Karen L Austin; Hyungjin Myra Kim; Donald R Miller; Susan V Eisen; Cindy L Christiansen; Amy M Kilbourne; Brian C Sauer; John F McCarthy; Marcia Valenstein
Journal:  BMC Psychiatry       Date:  2014-12-17       Impact factor: 3.630

9.  Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview.

Authors:  R J Baldessarini; L Tondo
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.